T1	p 143 170	major gynecologic surgery .
T2	p 353 437	ASA physical status I-III patients undergoing total abdominal hysterectomy ( TAH ) .
T3	p 718 726	patients
T4	p 873 882	sedated .
T5	i 22 95	prophylactic ondansetron , droperidol , perphenazine , and metoclopramide
T6	i 233 293	ondansetron , droperidol , perphenazine , and metoclopramide
T7	i 415 427	hysterectomy
T8	i 430 435	TAH )
T9	i 474 581	i.v. , one of ondansetron 4 mg , droperidol 1.25 mg , perphenazine 5 mg , metoclopramide 10 mg , or placebo
T10	i 665 679	metoclopramide
T11	i 733 744	ondansetron
T12	i 855 865	droperidol
T13	i 1069 1088	antiemetic rescue .
T14	i 1150 1161	ondansetron
T15	i 1173 1183	droperidol
T16	i 1199 1211	perphenazine
T17	i 1255 1262	placebo
T18	i 1285 1299	Metoclopramide
T19	i 1327 1370	ondansetron , droperidol , and perphenazine
T20	i 1435 1447	perphenazine
T21	i 1500 1512	perphenazine
T22	i 1565 1568	TAH
T23	o 117 136	nausea and vomiting
T24	o 188 207	antiemetic efficacy
T25	o 617 628	Hypotension
T26	o 764 784	systolic hypotension
T27	o 910 959	developing severe nausea , retching , or vomiting
T28	o 973 995	severe emetic sequelae
T29	o 1226 1230	free
T30	o 1460 1472	side effects